Literature DB >> 12030605

Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis.

A Lasco1, N Morabito, A Gaudio, A Crisafulli, A Meo, G Denuzzo, N Frisina.   

Abstract

Patients with beta-thalassaemia major are susceptible to osteopenia due to several factors which interfere with bone remodeling. It is known that bone metabolism and skeletal consolidation result from a complex sequence of hormonal changes, where the concerted actions of GH, IGF-I and sex hormones and their receptors, are responsible for the timing and attainment of skeletal consolidation. IGF-I and the corresponding binding protein (IGFBP-III), markers of bone metabolism and lumbar and femoral neck BMD were measured in 28 adult patients, undergoing hormonal replacement and chelation therapy and a hypertransfusion program, with beta-thalassaemia major (12 males with mean age 22.5+/-3.1 and 16 females with mean age 27.5+/-8.2), and in 28 healthy volunteers matched for age, anthropometric features and sex to the patients. BMD values, both at lumbar and femoral neck level were significantly lower (p<0.001 and p<0.05) by 18.7 and 4.2% respectively, in patients than in the controls. Markers of bone resorption [pyridinoline (Pyr) 78.1+/-15.7 vs 47.5+/-11.2 pmol/pmol urinary creatinine, p<0.001 and deoxypyridinoline (D-Pyr) 21.9+/-3.5 vs 14.5+/-5.4 pmol/ micromol urinary creatinine, p<0.001] were higher in patients than in controls, whereas the marker of bone formation was slightly lower [osteocalcin (BGP) 3.8+/-0.6 vs 4.6+/-1.7 pmol/ml, p<0.05]. Plasma levels of IGF-I (21.07+/-5.12 vs 35.25+/-8.33 nmol/ml, p<0.001) and IGF binding protein III (IGFBP-III) (1.9+/-0.4 vs 2.5+/-0.1 mg/ml, p<0.001) were lower in patients than in controls and positively correlated with BMD L2-L4 (r=0.57, p<0.05 and r=0.47, p<0.05 respectively), BMD neck (r=0.40, p<0.05 and r=0.34, p<0.05 respectively) and BGP (r=0.52, p<0.05 and r=0.34, p<0.05 respectively). Our beta-thalassaemic patients, in spite of normalizing hemoglobin levels, adequate hormone replacement and chelation therapies, showed osteopenia and an unbalanced bone turnover with an increased resorptive phase and a decreased formation phase probably correlated to low levels of IGF-I and IGFBP-III observed in our study.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12030605     DOI: 10.1007/bf03344015

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  36 in total

Review 1.  Endocrine abnormalities in thalassemia.

Authors:  C Vullo; V De Sanctis; M Katz; B Wonke; A V Hoffbrand; B Bagni; T Torresani; G Tolis; M Masiero; A Di Palma
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

Review 2.  Invited review of a workshop: anabolic hormones in bone: basic research and therapeutic potential.

Authors:  R N Margolis; E Canalis; N C Partridge
Journal:  J Clin Endocrinol Metab       Date:  1996-03       Impact factor: 5.958

3.  Novel application of IGF-I and IGFBP-3 generation tests in the diagnosis of growth hormone axis disturbances in children with beta-thalassaemia.

Authors:  D C Chrysis; T K Alexandrides; E Koromantzou; N Georgopoulos; P Vassilakos; W Kiess; J Kratsch; N G Beratis; B E Spiliotis
Journal:  Clin Endocrinol (Oxf)       Date:  2001-02       Impact factor: 3.478

4.  Normal growth hormone (GH) response to GH-releasing hormone in children with thalassemia major before puberty: a possible age-related effect.

Authors:  J Leger; R Girot; H Crosnier; M C Postel-Vinay; R Rappaport
Journal:  J Clin Endocrinol Metab       Date:  1989-08       Impact factor: 5.958

5.  Evaluation of hypothalamic-pituitary function in patients with thalassemia major.

Authors:  L Danesi; M Scacchi; M De Martin; A Dubini; P Massaro; A T Majolo; F Cavagnini; E E Polli
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

6.  Bone mineral metabolism in adults with beta-thalassaemia major and intermedia.

Authors:  R Dresner Pollack; E Rachmilewitz; A Blumenfeld; M Idelson; A W Goldfarb
Journal:  Br J Haematol       Date:  2000-12       Impact factor: 6.998

7.  Insulin-like growth factor I supports differentiation of cultured osteoblast-like cells.

Authors:  C Schmid; T Steiner; E R Froesch
Journal:  FEBS Lett       Date:  1984-07-23       Impact factor: 4.124

Review 8.  The insulin-like growth factor system and the coupling of formation to resorption.

Authors:  J M Hayden; S Mohan; D J Baylink
Journal:  Bone       Date:  1995-08       Impact factor: 4.398

9.  Circadian growth hormone secretion in short multitransfused prepubertal children with thalassaemia major.

Authors:  G Katzos; F Harsoulis; M Papadopoulou; M Athanasiou; K Sava
Journal:  Eur J Pediatr       Date:  1995-06       Impact factor: 3.183

10.  The laboratory diagnosis of haemoglobinopathies.

Authors: 
Journal:  Br J Haematol       Date:  1998-06       Impact factor: 6.998

View more
  9 in total

1.  A 2-year prospective densitometric study on the influence of Fok-I gene polymorphism in young patients with thalassaemia major.

Authors:  M Dimitriadou; A Christoforidis; L Fidani; M Economou; E Vlachaki; M Athanassiou-Metaxa; G Katzos
Journal:  Osteoporos Int       Date:  2015-08-15       Impact factor: 4.507

Review 2.  Growth and endocrine function in thalassemia major in childhood and adolescence.

Authors:  M Delvecchio; L Cavallo
Journal:  J Endocrinol Invest       Date:  2010-01       Impact factor: 4.256

3.  Effects of strontium ranelate on bone mass and bone turnover in women with thalassemia major-related osteoporosis.

Authors:  Nunziata Morabito; Antonino Catalano; Agostino Gaudio; Elisabetta Morini; Lucia Maria Bruno; Giorgio Basile; Eleni Tsiantouli; Federica Bellone; Rita Maria Agostino; Basilia Piraino; Maria Angela La Rosa; Carmelo Salpietro; Antonino Lasco
Journal:  J Bone Miner Metab       Date:  2015-07-24       Impact factor: 2.626

Review 4.  Bisphosphonates in the treatment of thalassemia-associated osteoporosis.

Authors:  A Gaudio; N Morabito; A Xourafa; I Macrì; A Meo; S Morgante; A Trifiletti; A Lasco; N Frisina
Journal:  J Endocrinol Invest       Date:  2008-02       Impact factor: 4.256

5.  Growth hormone reserve in adult beta thalassemia patients.

Authors:  Guy Vidergor; Ada W Goldfarb; Benjamin Glaser; Rivka Dresner-Pollak
Journal:  Endocrine       Date:  2007-02       Impact factor: 3.633

6.  Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial.

Authors:  Ersi Voskaridou; Ioannis Ntanasis-Stathopoulos; Athanasios Papaefstathiou; Dimitrios Christoulas; Maria Dimopoulou; Konstantina Repa; Athanasios Papatheodorou; Melpomeni Peppa; Evangelos Terpos
Journal:  Blood Adv       Date:  2018-11-13

7.  Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience.

Authors:  Irene Gagliardi; Mariella Celico; Maria Rita Gamberini; Margherita Pontrelli; Monica Fortini; Aldo Carnevale; Nicola Napoli; Maria Chiara Zatelli; Maria Rosaria Ambrosio
Journal:  Calcif Tissue Int       Date:  2022-03-04       Impact factor: 4.000

Review 8.  Hematological Diseases and Osteoporosis.

Authors:  Agostino Gaudio; Anastasia Xourafa; Rosario Rapisarda; Luca Zanoli; Salvatore Santo Signorelli; Pietro Castellino
Journal:  Int J Mol Sci       Date:  2020-05-16       Impact factor: 5.923

9.  Plasma proteome profiling combined with clinical and genetic features reveals the pathophysiological characteristics of β-thalassemia.

Authors:  Na Li; Peng An; Jifeng Wang; Tingting Zhang; Xiaoqing Qing; Bowen Wu; Lang Sun; Xiang Ding; Lili Niu; Zhensheng Xie; Mengmeng Zhang; Xiaojing Guo; Xiulan Chen; Tanxi Cai; Jianming Luo; Fudi Wang; Fuquan Yang
Journal:  iScience       Date:  2022-03-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.